ILiAD Biotechnologies, LLC is a clinical-stage biotechnology company founded with the mission to prevent and treat diseases caused by Bordetella pertussis. The company's vision is to eliminate the global burden of pertussis through innovative vaccine development. ILiAD Biotechnologies focuses on creating advanced vaccines that serve patients and healthcare providers, particularly in the State of California.
Notable affiliated individuals include experienced scientists and healthcare professionals dedicated to infectious disease research. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements include successful clinical trials demonstrating the efficacy of their pertussis vaccine candidates, positioning ILiAD Biotechnologies as a leader in the fight against whooping cough. Their work has the potential to significantly reduce pertussis-related morbidity and mortality worldwide.
